Fredun Pharmaceuticals Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Fredun Pharmaceuticals Ltd is ₹ 2299 as of 04 May 10:44 . The P/E Ratio of Fredun Pharmaceuticals Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Fredun Pharmaceuticals Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 160.92 crore as compare to the Sep '25 revenue of ₹ 145.29 crore. This represent the growth of 10.76% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 22.33 crore. This represent the growth of 17.96% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Fredun Pharmaceuticals Ltd changed from ₹ 13.74 crore to ₹ 10.48 crore over 5 quarters. This represents a CAGR of -19.48% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Fredun Pharmaceuticals Ltd changed from 13.9 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Fredun Pharmaceuticals Ltd

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94.
The Company was promoted by Nariman Medhora and Daulat N Medhora.
The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations.
Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy.
The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Fredun Pharmaceuticals Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Fredun Pharmaceuticals Ltd or Syncom Formulations (India) Ltd?

Market cap of Fredun Pharmaceuticals Ltd is 1,229 Cr while Market cap of Syncom Formulations (India) Ltd is 1,290 Cr

What are the key factors driving the stock performance of Fredun Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

The stock performance of Fredun Pharmaceuticals Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fredun Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

As of May 4, 2026, the Fredun Pharmaceuticals Ltd stock price is INR ₹2230.9. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹13.73.

How do dividend payouts of Fredun Pharmaceuticals Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Fredun Pharmaceuticals Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.